Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

This study has been terminated.
(poor accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00005834
First received: June 2, 2000
Last updated: March 5, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2007
  Primary Completion Date: November 2003 (Final data collection date for primary outcome measure)